Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 11, 2016 3:34 PM ET


Company Overview of Alcobra Ltd.

Company Overview

Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company is primarily developing MDX (metadoxine), an onset/extended release formulation of the chemical pyridoxine pyroglutamate, which is in Phase III clinical trial for adults with attention deficit hyperactivity disorder (ADHD); in Phase II clinical trial for pediatric with ADHD; and in Phase II clinical trial in adolescents and adults with Fragile X Syndrome. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel.

Amot Investment Building

9th Floor

2 Weizman Street

Tel Aviv,  6423902


Founded in 2008

13 Employees


972 72 220 4661

Key Executives for Alcobra Ltd.

Alcobra Ltd. does not have any Key Executives recorded.

Alcobra Ltd. Key Developments

Alcobra Ltd.(NasdaqGM:ADHD) added to NASDAQ Biotechnology Index

Alcobra Ltd. has been added to NASDAQ Biotech Index.

Alcobra Ltd. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 08:30 AM

Alcobra Ltd. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 08:30 AM. Venue: The Waldorf Astoria, 301 Park Avenue, New York, New York, United States. Speakers: Yaron Daniely, Chief Executive Officer, President and Director.

Alcobra Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended September 30, 2015

Alcobra Ltd. reported unaudited consolidated earnings results for the six months ended September 30, 2015. For the period, the company reported loss before income taxes was $10,273,000 compared to $15,531,000 a year ago. Net loss attributable to holders of ordinary shares was $10,300,000 or $0.50 per basic and diluted share compared to $15,546,000 or $1.14 per basic and diluted share a year ago. Net cash used in operating activities was $8,486,000 against $11,096,000 a year ago. Purchase of property and equipment was $36,000 against $70,000 a year ago.

Similar Private Companies By Industry

Company Name Region
Unipharm Ltd. Middle East/Africa
Life Science Research Israel, Ltd. Middle East/Africa
PainReform Ltd. Middle East/Africa
Rafa Laboratories Ltd. Middle East/Africa
ABIC Biological Laboratories Ltd. Middle East/Africa

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Alcobra Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at